Journal of Surgical Research
Volume 138, Issue 2 , Pages 198-204 , April 2007

Anti-IL2 Induction in Liver Transplantation with 93% Rejection-Free Patient and Graft Survival at 18 Months

Presented at the 1st Annual Academic Surgical Congress (Association for Academic Surgery), San Diego, CA, February 7–11, 2006.

Received 12 January 2006

References 

  1. Shapiro R, Young JB, Milford EL, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transpl. 2005;5:874
  2. Brennan DC. Action, efficacy and toxicities: polyclonal anti-lymphocyte antibodies. In:  Norman DJ,  Turka LA editor. Primer on Transplantation. (ed. 2). Mt. Laurel, NJ: American Society of Transplantation; 2001;p. 152
  3. Nashan B, Moore R, Amlot P, et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 1997;350:1193
  4. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995;60:748
  5. Kahan BD, Rajagopalan PR, Hall M United States Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2- receptor monoclonal antibody. Transplantation. 1999;67:276
  6. Vincenti F, Kirkman R, Light S, et al. Daclizumab Triple Therapy Study Group Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med. 1998;338:161
  7. Ponticelli C, Yussim A, Cambi V, et al. Simulect Phase IV Study Group A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation. 2001;72:1261
  8. Lawen JG, Davies EA, Mourad G, et al. Simulect International Study Group Randomized, double blind study of immuno-prophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil- containing triple therapy in renal transplantation. Transplantation. 2003;75:37
  9. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric interleukin 2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002;8:123
  10. Neuhaus P, Clavien PA, Kittur D, et al. CHIC 304 International Liver Study Group Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double blind randomized placebo controlled trial. Liver Transpl. 2002;8:132
  11. Filipponi F, Callea F, Salizzoni M, et al. Double blind comparison of hepatitis C histological recurrence rate in HCV + liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation. 2004;78:1488
  12. Marino IR, Doria C, Scott V, et al. Efficacy and safety of basiliximab with a tacrolimus based regimen in liver transplant recipients. Transplantation. 2004;78:886
  13. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25:658
  14. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372
  15. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000;31:241
  16. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638
  17. McAlister V, Grant D, Roy A, et al. Post-transplant lympho-proliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression. Transplant Proc. 1993;25:1400
  18. Gane E, Nauomov N, Qian K, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996;110:167
  19. Asfar S, Metrakos P, Fryer J, et al. Analysis of late deaths after liver transplantation. Transplantation. 1996;61:1377
  20. Kovarik JM, Breidenbach T, Gerbeau C, et al. Disposition and immunodynamics of Basiliximab in liver allograft recipients. Clin Pharmacol Ther. 1998;64:66
  21. Kovarik JM, Nashan B, Neuhaus P, et al. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther. 2001;69:201
  22. Jain A, Kashyap R, Dodson F, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation. 2001;72:1091
  23. Singh N, Gayowski T, Wannstedt CF, et al. Interferon alpha therapy for hepatitis C virus recurrence after liver transplantation: long term response with maintenance therapy. Clin Transplant. 1996;10:348
  24. Gayowski T, Singh N, Marino IR, et al. Hepatitis C genotypes in liver transplant recipients: impact on post-transplant recurrence, infections, response to interferon-α therapy and outcome. Transplantation. 1997;64:422
  25. Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology. 1996;23:971
  26. Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histological patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation. 1996;61:701
  27. Eason JD, Nair S, Cohen AJ, et al. Steroid free liver transplantation using rabbit anti-thymocyte globulin and early tacrolimus monotherapy. Transplantation. 2003;75:1396
  28. Belli L, Alberti A, Vangeli M, et al. Tapering off steroids 3 months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl. 2003;9:201
  29. Brillianti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl. 2002;8:884
  30. Kato T, Neff G, Montalbano M, et al. Steroid-free induction with tacrolimus and daclizumab in liver transplant recipients with hepatitis C: a preliminary report of a prospective randomized trial. Am J Transpl. 2001;1(suppl 1):179
  31. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation: an analysis of 101 cases. Medicine (Baltimore). 1988;67:132
  32. Paya CV, Hermans PE, Washington JA, et al. Incidence, distribution and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc. 1989;64:555

PII: S0022-4804(06)00465-3

doi: 10.1016/j.jss.2006.08.025

Journal of Surgical Research
Volume 138, Issue 2 , Pages 198-204 , April 2007

Article Tools

* Image Usage & Resolution